Dimethyl fumarate (trade name: Skilarence) has been approved in Germany since June 2017 for the systemic treatment of moderate to severe plaque psoriasis in adults.
Psoriasis is a non-contagious inflammatory skin disease. The symptoms usually include clearly defined red patches (called "plaques"), scaly skin and often itching too. They come and go in bouts: The skin can get better on its own, but it may also suddenly get worse. Psoriasis is a chronic (long-lasting) condition that currently has no cure.
It is usually treated with medications applied directly to the skin (topically), for instance with creams or ointments. Phototherapy is an option for people with more severe psoriasis. There are also drugs designed to decrease or stop the inflammation in different ways. They can either be taken as tablets or injected into the bloodstream. This form of treatment is called systemic treatment.
The drug is available in the form of tablets, in two different doses (30 and 120 mg). The dose should be increased gradually:
- 30 mg a day during the first week
- 60 mg a day during the second week
- 90 mg a day during the third week
- 120 mg a day during the fourth week
- From the fifth week on, the dose is increased by 120 mg per week until the maximum daily dose of 720 mg is reached.
The dose can be adjusted depending on intolerances, success of the treatment, or blood values.
For people with moderate to severe plaque psoriasis who are able to have systemic treatment, psoralen plus ultraviolet A therapy (PUVA) is an option, as well as the drugs fumaric acid ester, ciclosporin, methotrexate or secukinumab.
For people who have had unsuccessful systemic treatment with PUVA, ciclosporin or methotrexate, or who can't have these treatments because they are not suitable, treatment with a tumor necrosis factor (TNF) α inhibitor (adalimumab or infliximab), secukinumab or ustekinumab are options.
In 2017, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to look into the advantages and disadvantages of dimethyl fumarate compared with the standard treatments for moderate to severe plaque psoriasis in adults.
But the manufacturer did not provide any suitable data with which to do the assessment.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of dimethyl fumarate (Skilarence).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dimethyl fumarate (psoriasis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-49. December 22, 2017. (IQWiG reports; Volume 573).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.